Gujarat Themis Biosyn Limited (BOM:506879)
India · Delayed Price · Currency is INR | Market Cap | 42.60B |
| Revenue (ttm) | 1.51B |
| Net Income (ttm) | 487.72M |
| Shares Out | 108.97M |
| EPS (ttm) | 4.48 |
| PE Ratio | 87.27 |
| Forward PE | n/a |
| Dividend | 0.67 (0.17%) |
| Ex-Dividend Date | n/a |
| Volume | 41,933 |
| Average Volume | 22,222 |
| Open | 365.80 |
| Previous Close | 367.70 |
| Day's Range | 364.60 - 393.00 |
| 52-Week Range | 192.35 - 390.35 |
| Beta | -0.51 |
| RSI | 68.43 |
| Earnings Date | Aug 11, 2025 |
About Lumos Pharma
Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis; Rifamycin-O; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India. [Read more]
Financial Performance
In 2024, Gujarat Themis Biosyn's revenue was 1.51 billion, a decrease of -11.20% compared to the previous year's 1.70 billion. Earnings were 487.72 million, a decrease of -17.56%.
Financial StatementsNews
Gujarat Themis Biosyn starts commercial production at new API plant in Vapi, Gujarat
Gujarat Themis Biosyn Ltd. has commenced commercial production at its newly established Active Pharmaceutical Ingredient (API) manufacturing facility located at 69/C, GIDC Industrial Estate, Vapi – 39...
Themis Medicare shares surge nearly 2% following amalgamation announcement
Shares of Themis Medicare climbed 1.15% to ₹289.20 on the NSE as of 9:53 AM after the company announced its decision to merge Gujarat Themis Biosyn Limited (GTBL) with Themis Medicare Limited (TML). T...